Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Ivor R. Elrifi
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 10
- Beta
- 0.46
- Country
- GB
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -11.77
Financials
Revenue
$0.00-100.0%Net Income
$-12.39MEBITDA
$-12.23MFree Cash Flow
$-7.42MEPS (diluted)
$-0.10Shares Outstanding (diluted)
127.87M+503777.2%Operating Expenses
$6.43MCash & Debt
$3.18MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-18.43M | $-0.16 |
| 2024 | $0.00 | $-11.86M | $-0.11 |
| 2023 | $0.00 | $-17.69M | $-0.17 |
| 2022 | $0.00 | $-15.40M | $-0.15 |
| 2021 | $0.00 | $-31.59M | $-0.32 |
| 2020 | $0.00 | $-35.54M | $-0.37 |
| 2019 | $0.00 | $-9.36M | $-0.07 |
| 2018 | $0.00 | $-7.98M | $-0.06 |
| 2017 | $0.00 | $-6.77M | $-0.06 |
| 2016 | $0.00 | $-7.21M | $-0.07 |
| 2015 | $0.00 | $-8.63M | $-0.09 |
| 2014 | $0.00 | $-3.51M | $-0.31 |
| 2013 | $3.0K | $-280.0K | $-0.01 |
| 2012 | $0.00 | $-848.0K | $-0.47 |
Valuation
TLSAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70+40.00%Social Signal Score
Mentions (10)
- Newsseekingalpha.com·13d ago·Positive
Tiziana Life Sciences Ltd (TLSA) Discusses Positive Phase 2a INFORM-MS Results for Intranasal Foralumab in Nonactive Secondary Progressive Multiple Sclerosis Transcript Tiziana Life Sciences Ltd (TLSA) Discusses Positive Phase 2a INFORM-MS Results for Intranasal Foralumab in Nonactive Secondary Progressive Multiple Sclerosis Transcript
View source ↗ - Newsglobenewswire.com·17d ago·Neutral
…r Call with Key Opinion Leaders to Discuss Positive Phase 2a INFORM-MS Topline Results BOSTON, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, today announced that it will host a conference call and webcast with Key Opinion Leaders (KOLs) to discuss the positive …
View source ↗ - Newsreuters.com·20d ago·Neutral
Tiziana's experimental MS treatment meets main goals in mid-stage study Tiziana's experimental MS treatment meets main goals in mid-stage study
View source ↗ - Newsproactiveinvestors.com·37d ago·Neutral
Tiziana completes dosing in Phase 2 Alzheimer's trial of intranasal foralumab Tiziana Life Sciences Ltd (NASDAQ:TLSA) said the last patient has begun dosing in its Phase 2 trial of intranasal foralumab in early or mild Alzheimer's disease, with topline data expected in the first quarter of 2027. The milestone completes enrollment and dosing initiation for all participants in the randomized, placebo-controlled study, the biotechnology company said.
View source ↗ - Newsglobenewswire.com·37d ago·Neutral
…ses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer's Disease BOSTON, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that the last patient has begun dosing in its Phase 2 randomized, placebo-controlled clinical trial eva…
View source ↗ - Newsproactiveinvestors.com·55d ago·Negative
Tiziana doses first three patients in ALS trial of nasal antibody foralumab Tiziana Life Sciences Ltd (NASDAQ:TLSA) said the first three participants have received their first dose of intranasal foralumab in a Phase 2a trial in people living with amyotrophic lateral sclerosis (ALS). The Healey ALS MyMatch BANYAN trial is testing foralumab, a fully human anti-CD3 monoclonal antibody, delivered as a nasal spray.
View source ↗ - Newsproactiveinvestors.com·66d ago·Negative
Tiziana Life Sciences partners with Saudi institutions on MS combination therapy trial Tiziana Life Sciences Ltd (NASDAQ:TLSA) has signed a Memorandum of Understanding with the King Abdullah International Medical Research Center (KAIMRC) and the Foundation for Neurologic Diseases to study its intranasal foralumab in combination with anti-CD20 therapy for multiple sclerosis patients. The planned trial will target relapsing-remitting multiple sclerosis (RRMS) patients who respond poorly to anti-CD…
View source ↗ - Newsproactiveinvestors.com·80d ago·Neutral
Tiziana Life Sciences gets Buy rating from BTIG on Treg-based approach to neurodegeneration Tiziana Life Sciences Ltd (NASDAQ:TLSA) was awarded a Buy rating with a $7 price target by BTIG, which pointed to the biotech's approach to modulating central nervous system inflammation as a potential leading treatment for neurodegenerative disease. The clinical-stage company is developing foralumab, an anti-CD3 antibody delivered via nasal spray, to stimulate regulatory T-cell (Treg) production and redu…
View source ↗ - Newsproactiveinvestors.com·90d ago·Neutral
Tiziana Life Sciences to present Phase 2a BANYAN trial data at ALS Nexus 2026 Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it will present a poster on its Phase 2a BANYAN clinical trial of intranasal foralumab at ALS Nexus 2026 in Orlando, Florida, on Monday. The presentation, titled “Phase 2a Trial of Intranasal Foralumab – BANYAN, a Healey ALS MyMatch Trial,” is scheduled for 4:30 pm to 6:30 pm Eastern Time during the Scientific Poster Session.
View source ↗ - Newsglobenewswire.com·90d ago·Neutral
…esentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026 BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that a poster, titled “Phase 2a Trial of Intranasal Foralumab – BANYAN, a Healey ALS MyMatch Trial,” wi…
View source ↗
Earnings
Typical surprise -35.4% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Oct 16$-0.08 vs $-0.08miss
- Fri, May 1$-0.22 vs $-0.09miss
- Fri, Oct 3$-0.10 vs $-0.07miss
Estimates and results for TLSA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TLSA officers and directors.
- Bought
- $1.0m
- Sold
- —
5 trades
0 trades
- Elrifi Ivorbought
- Elrifi Ivorbought
- Elrifi Ivorbought
- Cerrone Gabriele Mbought
- Cerrone Gabriele Mbought
16 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in TLSA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
